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Summary
Background: Studies in Western populations have shown the beneﬁts of pretreatment with ator-
vastatin in preventing cardiovascular events in patients, including those with acute coronary
syndromes (ACS), undergoing percutaneous coronary intervention (PCI). However, data con-
cerning the value of such therapy in Asian patients are limited. The primary objective of the
present study is to evaluate the efﬁcacy of atorvastatin in reducing cardiovascular outcomes in
Asian patients with non-ST-segment elevation (NSTE)-ACS following hospital admission for early
PCI (within 72 h of the onset of symptoms). Secondary objectives are to assess the effects of
atorvastatin on cardiac biomarker levels, and the safety and tolerability proﬁle of atorvastatin.
Methods: This study is a prospective, multicenter, open-label trial designed to enroll 350 statin-
naïve patients with NSTE-ACS scheduled for PCI in China and the Republic of Korea. Patients
are randomized to either usual care or atorvastatin treatment groups, with patients in both
treatment groups receiving usual care including atorvastatin 40mg/day for 30 days post-PCI.
Patients in the atorvastatin group receive additional doses of atorvastatin 80mg at 12 h pre-PCI
and 40mg at 2 h pre-PCI. The primary end point is the incidence of major adverse cardiac events
(death, myocardial infarction, and target vessel revascularization) at 30 days post-PCI.
∗ Corresponding author. Tel.: +82 53 620 4671; fax: +82 53 621 3310.
E-mail address: yjkim@med.yu.ac.kr (Y.-J. Kim).
914-5087/$ — see front matter © 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jjcc.2009.12.002
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Conclusions: The present study will provide valuable insights into whether the beneﬁts of ator-
vastatin pretreatment extend to Asian patients with ACS undergoing interventions. Enhanced
treatment of these patients will be an important contribution towards alleviating the increasing
ase in Asian countries.
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ination, vital signs, electrocardiogram (ECG), and blood
sampling for laboratory tests: hematology, lipids, biochem-
istry, C-reactive protein (CRP), urinalysis, and biomarkersburden of cardiovascular dise
© 2010 Japanese College of C
ntroduction
ardiovascular disease (CVD) is the leading cause of death
oth worldwide and in Asia. In 2002, CVD accounted for 32%
f deaths in the Western Paciﬁc region [1]. Between 1993
nd 2003, the prevalence (per 1000) of CVD in China rose
rom 31.4 to 50.0 [2]. The burden of CVD in the Republic
f Korea has been measured at 1492 disability-adjusted life
ears (DALY) per 100,000 of the population, second only to
ancer (1525 DALY) [3]. As elsewhere, CVD is also detrimen-
al to economies in Asia. The Chinese economy is expected
o lose $558 billion over the decade from 2006 to 2015 due
o heart disease, stroke, and diabetes [4].
Lowering of low-density lipoprotein cholesterol (LDL-
) using 3-hydroxy-3-methylglutaryl coenzyme A reductase
nhibitors (statins) is a cornerstone of therapy for reducing
he risk of major fatal and nonfatal cardiovascular events.
he ability to achieve target LDL-C levels more quickly would
e particularly beneﬁcial in attempting to prevent CVD.
he reduced cardiovascular-related morbidity and mortal-
ty achieved with atorvastatin therapy has been proven
hroughout atorvastatin’s landmark studies across a range of
atient groups [5—9], including patients with acute coronary
yndromes (ACS) [5,10].
In the Atorvastatin for Reduction of MYocardial Damage
uring Angioplasty (ARMYDA) trial, 153 patients with sta-
le angina and without previous statin treatment undergoing
lective percutaneous coronary intervention (PCI) were ran-
omized to either 7 days of pretreatment with atorvastatin
0mg/day or placebo. Atorvastatin treatment was asso-
iated with a signiﬁcant 81% decrease in periprocedural
yocardial infarction (MI) (odds ratio [OR] 0.19; 95% con-
dence interval [CI] 0.05—0.57) [11]. About two-thirds of
ll patients undergoing coronary angioplasty have ACS [12],
nd the subsequent ARMYDA-ACS study of 171 statin-naïve
atients with non-ST-segment elevation (NSTE)-ACS was
erformed to assess whether the beneﬁts of pre-PCI ator-
astatin administration extend to such patients. Compared
ith placebo, a single high-dose (80mg) pretreatment with
torvastatin reduced major adverse cardiac events (MACE)
y 88% (p = 0.004) in ACS patients at 30 days after undergo-
ng an early invasive strategy (coronary angiography within
8 h, immediately followed by PCI) [13]. Most recently,
he ARMYDA-RECAPTURE study showed that these ﬁndings
lso applied in a population of 383 patients who were
lready receiving chronic statin therapy. Patients receiv-
ng additional atorvastatin doses of 80mg at 12 h pre-PCI
nd 40mg at 2 h pre-PCI experienced fewer MACE at 30
ays post-PCI, compared with those receiving placebo (4%
s. 9%; p = 0.037). The beneﬁt was found to be driven by
particularly strong effect on MACE among patients with
STE-ACS (82% relative risk reduction; p = 0.027) [14]. In sup-
ort of the ﬁndings from the ARMYDA trials, the beneﬁt of
high loading dose of atorvastatin was demonstrated in the
o
a
a
cology. Published by Elsevier Ireland Ltd. All rights reserved.
ovel Approaches for Preventing or Limiting Events (NAPLES)
I trial of 668 patients scheduled for PCI who were not
eceiving statin therapy. Compared with placebo, patients
eceiving a single dose of atorvastatin 80mg within 24 h
rior to PCI experienced a 44% reduction in periprocedural
on-Q-wave MI (p = 0.014) [15].
Due to potential differences among populations in
esponse to statin treatment, it is important to determine
hether key ﬁndings from studies conducted in Western pop-
lations, such as the ARMYDA studies, are also applicable to
sian patients. Here we describe the design of the Asian Lip-
tor Pretreatment in ACS (ALPACS) study. A similar treatment
aradigm to that of the ARMYDA-ACS study is being used to
valuate the efﬁcacy and safety of a high pretreatment dose
f atorvastatin in statin-naïve Asian patients with NSTE-ACS
nd LDL-C ≥80mg/dl undergoing early PCI (within 72 h of
he onset of symptoms). The primary objective is to eval-
ate the efﬁcacy of atorvastatin in reducing cardiovascular
utcomes in Asian patients with NSTE-ACS following hospi-
al admission for early PCI. The secondary objectives are to
valuate the effects of atorvastatin on cardiac biomarker
evels, and the safety and tolerability proﬁle of atorvas-
atin in the presence of underlying usual care in this patient
opulation.
ethods
tudy design
he study is a 30-day, prospective, multicenter, randomized,
pen-label trial of statin-naïve patients at 26 investigation
ites (12 in China and 14 in the Republic of Korea; Fig. 1).
o be eligible for enrolment, patients must be Asian and
ged ≥18 years with screening LDL-C ≥80mg/dl, and must
ave NSTE-ACS (unstable angina with coronary angiography
o be undertaken within 72 h of the onset of symptoms of
nstability, or NSTE-acute MI with coronary angiography to be
ndertaken within 72 h of the onset of symptoms). Patients
ust also complete a consent document, and must be will-
ng and able to comply with scheduled visits, the treatment
lan, laboratory tests, and other study procedures.
Screening occurs within 72 h prior to PCI. Patients are
ssessed at 12 h pre-PCI, 2 h pre-PCI, 8 h post-PCI, 24 h
ost-PCI, and at end of treatment (30 days post-PCI) or
arly discontinuation. Assessments include physical exam-f myocardial injury (creatinine kinase [CK]-MB, myoglobin,
nd troponin-I [or troponin-T if troponin-I testing is not avail-
ble]).
Eligible patients are randomized to either the usual
are or atorvastatin treatment groups. All patients receive
Asian atorvastatin pretreatment in ACS 305
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aFigure 1 Study design. MACE, major adverse cardiac events; N
percutaneous coronary intervention.
usual care in terms of routine dietary intervention consis-
tent with local hospital practice. Both treatment groups
receive usual care treatments, which include aspirin
(aspirin-naïve patients, 200—300mg loading dose pre-PCI
and 100—200mg/day thereafter according to local practice;
patients already receiving aspirin at screening continue as
per their usual pre-study regimen), clopidogrel (300mg load-
ing dose at least 3 h pre-PCI and 75mg/day thereafter), and
subcutaneous heparin while in hospital (enoxaparin [1mg/kg
weight-adjusted, every 12 h pre-PCI and 12 hourly thereafter
during hospital stay, or for a minimum of 48 h post-PCI or
every 24 h if estimated creatinine clearance is <30ml/min]
or dalteparin [120 IU/kg weight-adjusted, every 12 h pre-
PCI and 12 hourly thereafter during hospital stay, or for a
minimum of 48 h post-PCI]).
Usual care treatments also include atorvastatin
40mg/day after PCI for 30 days. Patients in the ator-
vastatin group receive all of the usual care treatments,
as well as additional atorvastatin doses of 80mg at 12 h
pre-PCI and 40mg at 2 h pre-PCI.
Exclusion criteria and prohibited medications
Exclusion criteria include the following: previous or cur-
rent treatment with atorvastatin or other statins; female
patients who are pregnant, lactating, planning a pregnancy
during the course of the study, or who are of child-bearing
potential and not using an acceptable method of birth
control; ST-segment elevation acute MI; NSTE-ACS with
≥6 out of 7 risk features warranting emergency coronary
angiography [age ≥65 years, ≥3 risk factors for coronary
artery disease, prior coronary stenosis of ≥50%, ST-segment
deviation (≥0.05mV) on ECG at presentation, ≥2 anginal
events in prior 24 h, prior use of aspirin within 7 days,
elevated serum troponin-I or CK-MB]; impaired hepatic func-
tion; chronic active liver or muscle diseases; white blood
cell counts <4× 109/l or platelet counts <100× 109/l; renal
failure with creatinine >3mg/dl or creatinine clearance
<30ml/min; left ventricular ejection fraction (LVEF) <30% at
screening; history of intolerance or hypersensitivity to ator-
vastatin or other statins; medications that have a potential
for drug—drug interactions; glycoprotein IIb/IIIa inhibitors
as required medication; patients whose treatment with
angiotensin-converting enzyme (ACE) inhibitors, angiotensin
M
T
c
s-ACS, non-ST-segment elevation acute coronary syndrome; PCI,
eceptor blockers (ARB), beta-blockers, or calcium-channel
ntagonists has not remained stable within 1 month of
tudy enrolment; medications that are contraindicated in
he presence of co-administration with clopidogrel, aspirin,
nd heparin; participation in any other studies involving
nvestigational or marketed products within 1 month prior
o entry in the study; any condition rendering the patient
nable to understand the nature or scope of the study and/or
endering the patient to be unable or unlikely to follow the
rotocol; history of known alcohol or drug abuse within the
revious 12 months; or any condition that might increase the
isk to the patient for any adverse event (AE) or abnormal
aboratory ﬁnding.
Following the PCI procedure and for the dura-
ion of the study, patients are not allowed to take
nti-lipidemic medications including statins (other than
torvastatin 40mg/day), niacin, bile acid sequestrants,
holesterol absorption inhibitors (e.g. ezetimibe), psyl-
ium (>2 tablespoons/day), and ﬁsh oil. Cytochrome
450 inhibitors are also prohibited, including grapefruit
uice (>1.2 l/day), macrolide antibiotics, azole antifungals,
rotease inhibitors, immunosuppressive medications (i.e.
yclosporin), and verapamil. Glycoprotein IIb/IIIa inhibitors
nd unfractionated heparin are not to be used during the
tudy unless it is absolutely necessary for the individ-
al patient in the clinical management of intra-procedural
atheter thrombosis in accordance with the local product
nformation.
atient analysis sets and end points
he efﬁcacy analysis will be performed on the full analysis
et (FAS) and per-protocol (PP) set, with FAS as the pri-
ary analysis set. The FAS consists of all patients who have
eceived ≥1 dose of study medication and received PCI. The
P set consists of all patients who have received ≥1 dose of
tudy medication and received PCI per protocol. The safety
nalysis is conducted on the safety analysis set, consisting of
ll patients who have received ≥1 dose of study medication.The primary end point is the incidence of MACE (death,
I, and target vessel revascularization) at 30 days post-PCI.
he use of troponin levels for the diagnosis of MI in the
linical setting of myocardial ischemia follows the criteria
peciﬁed by the European Society of Cardiology, Ameri-
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an College of Cardiology, American Heart Association, and
orld Heart Federation [16]. Diagnosis of spontaneous MI
equires elevated cardiac troponin-I with at least one value
bove the 99th percentile upper limit of normal (ULN) in
atients with normal baseline troponin values. Diagnosis
f PCI-associated MI requires elevated cardiac troponin-I
ith at least three times the 99th percentile ULN (together
ith ECG or imaging evidence in the case of patients with
bnormal baseline troponin levels). Diagnosis of reinfarction
equires abnormal baseline troponin levels together with
CG or imaging evidence and increasing troponin levels (tro-
onin must be measured immediately and 3—6h later; a 20%
ncrease satisﬁes the criteria for increasing troponin in these
atients; the value from the second sample must also exceed
he 99th percentile ULN).
Secondary efﬁcacy end points include the incidence of
ACE at 8 h and 24 h post-PCI, the proportion of patients
ith any cardiac biomarker (CK-MB, myoglobin, or troponin-
) levels above ULN range from baseline (at 8 h, 24 h, and 30
ays post-PCI), change from baseline in CRP levels (at 8 h,
4 h, and 30 days post-PCI), and the safety and tolerability
roﬁle of atorvastatin in the presence of underlying usual
are in this population.
tatistical methods
ased on the ﬁndings of the ARMYDA-ACS trial [13], the
resent study is powered to have a 90% chance of detect-
ng a difference in MACE incidence of 17% vs. 5% between
reatment groups within 30 days post-PCI. To achieve such
ower, 158 patients per treatment group need to complete
he study. Allowing for approximately 10% dropout, consis-
ent with the 10.5% dropout reported in ARMYDA-ACS [13],
he total ﬁnal sample size for the study is chosen to be 350
atients. Within each country, the usual care and atorvas-
atin groups are equally sized.
The overall incidence rate of MACE in each treatment
roup is deﬁned as the number of patients who experienced
ACE within 30 days post-PCI, divided by the number of
atients who underwent PCI. The null hypothesis of no dif-
erence between the MACE incidence rates in the treatment
roups is tested using a two-sided continuity corrected 2-
est with a type I error rate of 5%, and a p-value is provided.
he 95% CI for the true difference in the incidence of MACE
etween treatment groups is calculated. Using the same
ethods, separate analyses are conducted for the three
omponents of MACE at 30 days post-PCI. Fisher’s exact test
s used whenever the expected frequency of events in these
dditional analyses is <5%.
The OR and 95% CI for comparing the odds of MACE
t 30 days post-PCI are calculated using a logistic regres-
ion analysis. An unadjusted OR and 95% CI are calculated
y including treatment group as the only covariate in the
ogistic regression model. An adjusted OR and 95% CI are
alculated by including treatment group and the following
otential confounding covariates in the logistic regression
odel: NSTE-MI; LVEF ≤40%; and use of ACE inhibitors, ARB,
eta-blockers, calcium-channel antagonists, or diuretics.
he logistic regression analyses are also applied to individ-
al MACE components. Using the Kaplan—Meier method with
he log-rank test, event-free comparisons up to 30 days post-
m
m
e
i
iJ. Ge et al.
CI between treatment groups are performed for MACE and
eparately for MI events.
The overall incident rate of MACE is also compared
etween treatment groups at 8 h and 24 h post-PCI. The per-
entages of patients who have elevated post-PCI levels of
K-MB, myoglobin, and troponin-I are compared between
reatment groups at 8 h, 24 h, and 30 days post-PCI. p-Values
or testing the treatment difference against zero and 95% CI
re calculated. The average mean percent change in CRP
rom baseline in each treatment group is estimated using
NOVA analysis at 8 h, 24 h, and 30 days post-PCI. A statisti-
al comparison of the mean percent change in CRP between
reatment groups with 95% CI is also obtained.
Safety of atorvastatin is assessed by (1) the incidence,
everity, and relationship to treatment of AEs including clin-
cally signiﬁcant changes in vital signs, ECG, and physical
xamination ﬁndings, and (2) changes in laboratory parame-
ers. All AEs, signiﬁcant medical history terms, previous and
oncomitant non-drug treatments are coded using the Medi-
al Dictionary for Regulatory Activities (MedDRA) coding sys-
em. Previous and concomitant drug medications are coded
sing the World Health Organization Drug coding system.
thics
he study is conducted in accordance with the Declaration
f Helsinki on Ethical Principles for Medical Research Involv-
ng Human Patients, adopted by the General Assembly of
he World Medical Association (1996). In addition, the study
s conducted in accordance with the protocol, the Inter-
ational Conference on Harmonization Guideline on Good
linical Practice, and applicable local regulatory require-
ents and laws.
This trial is registered to www.clinicaltrials.gov as trial
umber NCT00728988.
iscussion
recent meta-analysis of studies in the Asia-Paciﬁc region
ound that all of the major cardiovascular risk factors are
t least as applicable in Eastern as in Western populations,
hus implying the relevance of Western treatment regimens
n Asia [17]. However, ethnic differences can occur in phar-
acologic responses to therapeutic drugs. An example of
uch a difference in the case of statins is that the beneﬁt
btained from a given dose in Caucasian patients can often
e achieved at lower doses in Asian patients [18]. There-
ore, following the insights gained from the ARMYDA group
f studies in Caucasian patients, it is important for stud-
es to be carried out to evaluate similar protocols in Asian
opulations.
A recent study undertaken in China compared the effects
f pretreatment for 7 days with standard (20mg/day) vs.
ntensive (80mg/day) simvastatin in ACS patients under-
oing PCI. Intensive treatment was found to improve
yocardial blood perfusion (measured using thrombolysis in
yocardial infarction [TIMI] scores) and to protect against
yocardial injury (assessed using CK-MB and troponin-I lev-
ls) [19]. The present study, which is being carried out
n statin-naïve patients from China and Korea, is evaluat-
ng the effect of pretreatment with high-dose atorvastatin
o
i
A
T
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R
[
[Asian atorvastatin pretreatment in ACS
compared with usual care on cardiovascular events using a
similar protocol to that of the ARMYDA-ACS study.
In the original ARMYDA trial, atorvastatin pretreatment
signiﬁcantly reduced periprocedural MI, as assessed by CK-
MB determination, compared with placebo [11]. Similarly, in
the ARMYDA-ACS study, pretreatment of ACS patients with
atorvastatin conferred a reduced risk of MACE at 30 days
after PCI compared with placebo, a beneﬁt that was driven
by a reduction in periprocedural MI [13]. Given the short
duration of these studies, the potential mechanism may be
related to pleiotropic effects of atorvastatin on the progres-
sion of atherosclerosis. Indeed, the ARMYDA-Cell Adhesion
Molecules (CAMS) study demonstrated that the reduced
myocardial injury associated with atorvastatin pretreat-
ment was accompanied by signiﬁcantly attenuated levels
of E-selectin and intracellular adhesion molecules, support-
ing a role for an anti-inﬂammatory mechanism [20]. The
pleiotropic effects may also contribute to further beneﬁts
seen in other ARMYDA studies, such as the anti-arrhythmic
action associated with atorvastatin pretreatment in the
ARMYDA-3 study [21], and the protection against contrast-
induced nephropathy observed in patients receiving statin
therapy before undergoing PCI [22]. Analysis of the CRP data
in the present study may provide further insight into the
non-lipid-lowering effects of atorvastatin pretreatment.
In addition to assessing MACE and its components, this
study is investigating levels of CK-MB, myoglobin, and
troponin-I, which serve as markers of myocardial necro-
sis. Elevation of CK-MB to any level above normal range
appears to be associated with an increased risk of death
after PCI. In ARMYDA-ACS, patients in the atorvastatin group
were less likely to have elevated levels of CK-MB (7% vs.
27% with placebo; p = 0.001) and troponin-I (41% vs. 58%,
p = 0.039) [13]. Similarly, in the original ARMYDA trial, the
incidences of increase in all biomarkers (CK-MB, myoglobin,
and troponin-I) 24 h post-PCI in patients with stable angina
were signiﬁcantly lower following pretreatment with ator-
vastatin 40mg/day for 7 days compared with placebo [11].
Atorvastatin was well tolerated in previous studies
with ACS populations [10,13]. The present study of Asian
patients with ACS is providing valuable safety data. Over-
all, compared with evidence in Caucasian populations, the
availability of statin safety data among Asian patients is
limited.
Taken together, the ARMYDA studies have provided impor-
tant insights into the protective effects that can be gained
from pretreatment with high-dose atorvastatin of patients
undergoing early PCI. The present study is important in eval-
uating whether the ﬁndings of the ARMYDA-ACS study extend
to an Asian population with NSTE-ACS.
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